NCT00489697View on ClinicalTrials.gov

Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases

NACompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Metastatic Colorectal Cancer
Interventions
DEVICE

real-time contrast-enhanced ultrasound imaging (CEUS)

Real time contrast enhanced sonography was performed using an ultrasound dedicated system after bolus injection of 1.2 and 2x2.4 ml Sonovue ® (Bracco, Milan, Italy)

Trial Locations (12)

25000

CHRU Besancon, Besançon

33075

Hôpital Saint-André, CHRU Bordeaux, Bordeaux

33604

Hôpital Haut-Lévêque, Pessac

35033

CHU Pontchaillou, Rennes

35042

CRLCC, Centre Eugène Marquis, Rennes

37044

Chru Tours, Tours

44805

CRLCC, Centre René Gauducheau, Nantes Saint Herblain

49033

CHRU d'ANGERS, Angers

CRLCC, Centre Paul Papin, Angers

51092

Hôpital Robert Debré, CHRU Reims, Reims

75651

Hôpital Pitié Salpétrière, Assistance Publique Hôpitaux de Paris, Paris

86000

Hôpital La Milétrie, CHRU Poitiers, Poitiers

All Listed Sponsors
lead

University Hospital, Tours

OTHER

NCT00489697 - Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases | Biotech Hunter | Biotech Hunter